MedPath

RECKITT BENCKISER INC

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

6

Active:0
Completed:6

Trial Phases

3 Phases

Phase 1:4
Phase 2:1
Phase 4:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials

Phase 1
4 (66.7%)
Phase 2
1 (16.7%)
Phase 4
1 (16.7%)

Bioequivalence Study Comparing Mucinex Extended-release 600 mg Tablets to Immediate-release Guaifenesin 600 mg in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
Drug: Vicks Cough Syrup for Chesty Coughs
First Posted Date
2018-08-23
Last Posted Date
2019-06-19
Lead Sponsor
Reckitt Benckiser Inc.
Target Recruit Count
30
Registration Number
NCT03644095

Study to Characterize the Pharmacokinetics of 3 Marketed Products Containing 200 mg Guaifenesin in Healthy Volunteers.

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
Drug: Robitussin Extra Strength Chest Congestion
Drug: Vicks Cough Syrup for Chesty Coughs
Drug: Organ-I- NR tablet
First Posted Date
2018-08-23
Last Posted Date
2019-03-27
Lead Sponsor
Reckitt Benckiser Inc.
Target Recruit Count
30
Registration Number
NCT03643575

Study to Evaluate the Pharmacokinetics of Mucinex 600 mg Extended-release Bi-layer Tablet in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
First Posted Date
2018-08-23
Last Posted Date
2019-02-28
Lead Sponsor
Reckitt Benckiser Inc.
Target Recruit Count
30
Registration Number
NCT03644108

Mucinex® ER 600 mg Bi-layer Tablet Versus Guaifenesin Immediate Release (IR) 200 mg q4h

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
First Posted Date
2018-08-22
Last Posted Date
2019-06-17
Lead Sponsor
Reckitt Benckiser Inc.
Target Recruit Count
30
Registration Number
NCT03642262

Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute RTI

Phase 4
Completed
Conditions
Acute Upper Respiratory Track Infection
Interventions
Device: Placebo
First Posted Date
2010-09-15
Last Posted Date
2020-12-30
Lead Sponsor
Reckitt Benckiser Inc.
Target Recruit Count
1179
Registration Number
NCT01202279
Locations
🇺🇸

Clinical Research Advantage, Inc., Mesa, Arizona, United States

🇺🇸

Med Center, Carmichael, California, United States

🇺🇸

Research Center of Fresno, 3636 N. First Street, Suite 141, Fresno, California, United States

and more 21 locations
  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.